Core Insights - The article highlights the role of the Xinchao Innovation Center in fostering innovation within the biopharmaceutical sector in Beijing, emphasizing its commitment to supporting original innovation and the exploration of the unknown [1][3][4]. Group 1: Company Overview - Xinchao Innovation Center has incubated 102 companies since its establishment in 2019, including projects from prestigious institutions like Tsinghua University and Harvard University [3]. - The center has facilitated the clinical trial phase for six globally innovative drugs and nurtured two unicorns and 25 national high-tech enterprises, with total financing exceeding 6.5 billion yuan [3]. - The center provides comprehensive support throughout the lifecycle of biopharmaceutical companies, aiming to lower barriers for scientists entering entrepreneurship [3][4]. Group 2: Industry Development - Beijing's biopharmaceutical industry is projected to exceed 1 trillion yuan in scale by 2024, with a reported value of 1.06 trillion yuan [6][5]. - The city has seen significant growth in its pharmaceutical sector, with 436 large-scale pharmaceutical enterprises generating approximately 185 billion yuan in output value [6]. - The "South-North Linkage" strategy is being implemented to enhance industrial upgrades, with the southern region focusing on the International Pharmaceutical Innovation Park and the northern region centered around the Zhongguancun Life Science Park [6][5]. Group 3: Policy and Support - Beijing has introduced a series of measures to promote high-quality development in the innovative pharmaceutical sector, including a reduction in clinical trial approval times from 60 days to 30 days [7][8]. - The new "32 measures" aim to support the pharmaceutical industry through various initiatives, such as expanding the training of project leaders and simplifying drug approval processes [8]. - A 10 billion yuan pharmaceutical merger fund has been established to further support the industry, alongside initiatives for talent acquisition and intellectual property protection [8].

近期，新京报贝壳财经记者走进中关村生命科学园，探寻北京生物医药产业的创新密码。 中关村生命科学园展厅内，陈列着多款创新医疗器械。 新京报贝壳财经记者丁爽 摄 步入北京新生巢生物医药科技产业运营有限公司（简称"新生巢创新中心"），一幅纵贯四至十层的巨幅壁画映入眼帘。画中凤凰振翅欲飞，气势磅礴，却唯 独没有画上眼睛——这处留白，正是新生巢的匠心所在。 正如新生巢创新中心政府事务负责人杨莉所阐释的："创新本身就是一场面向未知的探索。这条路或许充满不确定性，但其魅力恰恰在于对未来的无限向 往。我们坚信，创新的价值，在于'看见未看见，改变未改变'。在这条未来可期的道路上，新生巢愿始终作为同行者与支持者，与所有创新者一道探索前 沿，并肩前行。" 作为生物医药领域的产业运营服务商，新生巢创新中心为原始创新提供了萌芽的沃土。而其所在的中关村生命科学园更是创新成果的产业母体和加速器。 官方发布的数据显示，2024年北京全市医药健康产业规模实现万亿级跃升。在此背后，北京市强化"南北联动"，南部高质量建设国际医药创新公园，联动大 兴生物医药基地共同打造产业升级新引擎。北部依托中关村生命科学园，连通海淀区与昌平区，深耕国际医疗器械城 ...

Group 1 - The "Inviting Ice City: Living and Working in Gaoming" promotion event will be held in Harbin, aiming to establish a cooperative bridge between Gaoming and Harbin, focusing on tourism, industry, cultural tourism, and employment [1] - Gaoming is located at the core of the Guangdong-Hong Kong-Macao Greater Bay Area, attracting talent and capital due to its excellent living environment, public services, and vibrant investment atmosphere [1] - The construction of the new airport in Guangzhou is accelerating, and Gaoming is developing a comprehensive transportation system, positioning itself as a new hub for the Greater Bay Area [1] Group 2 - The promotion event will feature presentations from four departments in Gaoming, focusing on livability, cultural tourism resources, industrial opportunities, and employment policies [2] - A signing ceremony for cooperation agreements will take place, including long-term agreements between Gaoming's housing association and local real estate associations, as well as between participating real estate companies and the Heilongjiang Chamber of Commerce [2] - The collaboration aims to enhance resource complementarity and drive population growth, industrial cooperation, and capital influx into Gaoming [1][2]